Skip to content

Title 21 — Food and Drugs

Part D · Chapter 13 — Drug Abuse Prevention and Control

§ 842. Prohibited acts B

Statutory text

(a)

Unlawful acts

It shall be unlawful for any person—

(1)

who is subject to the requirements of part C to distribute or dispense a controlled substance in violation of section 829 of this title;

(2)

who is a registrant to distribute or dispense a controlled substance not authorized by his registration to another registrant or other authorized person or to manufacture a controlled substance not authorized by his registration;

(3)

who is a registrant to distribute a controlled substance in violation of section 825 of this title;

(4)

to remove, alter, or obliterate a symbol or label required by section 825 of this title;

(5)

to refuse or negligently fail to make, keep, or furnish any record, report, notification, declaration, order or order form, statement, invoice, or information required under this subchapter or subchapter II;

(6)

to refuse any entry into any premises or inspection authorized by this subchapter or subchapter II;

(7)

to remove, break, injure, or deface a seal placed upon controlled substances pursuant to section 824(f) or 881 of this title or to remove or dispose of substances so placed under seal;

(8)

to use, to his own advantage, or to reveal, other than to duly authorized officers or employees of the United States, or to the courts when relevant in any judicial proceeding under this subchapter or subchapter II, any information acquired in the course of an inspection authorized by this subchapter concerning any method or process which as a trade secret is entitled to protection, or to use to his own advantage or reveal (other than as authorized by section 830 of this title) any information that is confidential under such section;

(9)

who is a regulated person to engage in a regulated transaction without obtaining the identification required by 830(a)(3) of this title.1

(10)

negligently to fail to keep a record or make a report under section 830 of this title or negligently to fail to self-certify as required under section 830 of this title;

(11)

to distribute a laboratory supply to a person who uses, or attempts to use, that laboratory supply to manufacture a controlled substance or a listed chemical, in violation of this subchapter or subchapter II, with reckless disregard for the illegal uses to which such a laboratory supply will be put;

(12)

who is a regulated seller, or a distributor required to submit reports under subsection (b)(3) of section 830 of this title—

(A)

to sell at retail a scheduled listed chemical product in violation of paragraph (1) of subsection (d) of such section, knowing at the time of the transaction involved (independent of consulting the logbook under subsection (e)(1)(A)(iii) of such section) that the transaction is a violation; or

(B)

to knowingly or recklessly sell at retail such a product in violation of paragraph (2) of such subsection (d);

(13)

who is a regulated seller to knowingly or recklessly sell at retail a scheduled listed chemical product in violation of subsection (e) of such section;

(14)

who is a regulated seller or an employee or agent of such seller to disclose, in violation of regulations under subparagraph (C) of section 830(e)(1) of this title, information in logbooks under subparagraph (A)(iii) of such section, or to refuse to provide such a logbook to Federal, State, or local law enforcement authorities;

(15)

to distribute a scheduled listed chemical product to a regulated seller, or to a regulated person referred to in section 830(b)(3)(B) of this title, unless such regulated seller or regulated person is, at the time of such distribution, currently registered with the Drug Enforcement Administration, or on the list of persons referred to under section 830(e)(1)(B)(v) of this title;

(16)

to violate subsection (e) of section 825 of this title; 2 or

(17)

in the case of a registered manufacturer or distributor of opioids, to fail to review the most recent information, directly related to the customers of the manufacturer or distributor, made available by the Attorney General in accordance with section 827(f) of this title.

As used in paragraph (11), the term “laboratory supply” means a listed chemical or any chemical, substance, or item on a special surveillance list published by the Attorney General, which contains chemicals, products, materials, or equipment used in the manufacture of controlled substances and listed chemicals. For purposes of paragraph (11), there is a rebuttable presumption of reckless disregard at trial if the Attorney General notifies a firm in writing that a laboratory supply sold by the firm, or any other person or firm, has been used by a customer of the notified firm, or distributed further by that customer, for the unlawful production of controlled substances or listed chemicals a firm distributes and 2 weeks or more after the notification the notified firm distributes a laboratory supply to the customer. For purposes of paragraph (15), if the distributor is temporarily unable to access the list of persons referred to under section 830(e)(1)(B)(v) of this title, the distributor may rely on a written, faxed, or electronic copy of a certificate of self-certification submitted by the regulated seller or regulated person, provided the distributor confirms within 7 business days of the distribution that such regulated seller or regulated person is on the list referred to under section 830(e)(1)(B)(v) of this title.

(b)

Manufacture

It shall be unlawful for any person who is a registrant to manufacture a controlled substance in schedule I or II, or ephedrine, pseudoephedrine, or phenylpropanolamine or any of the salts, optical isomers, or salts of optical isomers of such chemical, which is—

(1)

not expressly authorized by his registration and by a quota assigned to him pursuant to section 826 of this title; or

(2)

in excess of a quota assigned to him pursuant to section 826 of this title.

(c)

Penalties

(1)
(A)

Except as provided in subparagraph (B), (C), or (D) of this paragraph and paragraph (2), any person who violates this section shall, with respect to any such violation, be subject to a civil penalty of not more than $25,000. The district courts of the United States (or, where there is no such court in the case of any territory or possession of the United States, then the court in such territory or possession having the jurisdiction of a district court of the United States in cases arising under the Constitution and laws of the United States) shall have jurisdiction in accordance with section 1355 of title 28 to enforce this paragraph.

(B)
(i)

Except as provided in clause (ii), in the case of a violation of paragraph (5), (10), or (17) of subsection (a), the civil penalty shall not exceed $10,000.

(ii)

In the case of a violation described in clause (i) committed by a registered manufacturer or distributor of opioids and related to the reporting of suspicious orders for opioids, failing to maintain effective controls against diversion of opioids, or failing to review the most recent information made available by the Attorney General in accordance with section 827(f) of this title, the penalty shall not exceed $100,000.

(C)

In the case of a violation of paragraph (16) of subsection (a) of this section by an importer, exporter, manufacturer, or distributor (other than as provided in subparagraph (D)), up to $500,000 per violation. For purposes of this subparagraph, a violation is defined as each instance of importation, exportation, manufacturing, distribution, or possession with intent to manufacture or distribute, in violation of paragraph (16) of subsection (a).

(D)

In the case of a distribution, dispensing, or possession with intent to distribute or dispense in violation of paragraph (16) of subsection (a) of this section at the retail level, up to $1000 per violation. For purposes of this paragraph, the term “at the retail level” refers to products sold, or held for sale, directly to the consumer for personal use. Each package, container or other separate unit containing an anabolic steroid that is distributed, dispensed, or possessed with intent to distribute or dispense at the retail level in violation of such paragraph (16) of subsection (a) shall be considered a separate violation.

(2)
(A)

If a violation of this section is prosecuted by an information or indictment which alleges that the violation was committed knowingly and the trier of fact specifically finds that the violation was so committed, such person shall, except as otherwise provided in subparagraph (B) or (D) of this paragraph, be sentenced to imprisonment of not more than one year or a fine under title 18, or both.

(B)

If a violation referred to in subparagraph (A) was committed after one or more prior convictions of the offender for an offense punishable under this paragraph (2), or for a crime under any other provision of this subchapter or subchapter II or other law of the United States relating to narcotic drugs, marihuana, or depressant or stimulant substances, have become final, such person shall be sentenced to a term of imprisonment of not more than 2 years, a fine under title 18, or both.

(C)

In addition to the penalties set forth elsewhere in this subchapter or subchapter II, any business that violates paragraph (11) of subsection (a) shall, with respect to the first such violation, be subject to a civil penalty of not more than $250,000, but shall not be subject to criminal penalties under this section, and shall, for any succeeding violation, be subject to a civil fine of not more than $250,000 or double the last previously imposed penalty, whichever is greater.

(D)

In the case of a violation described in subparagraph (A) that was a violation of paragraph (5), (10), or (17) of subsection (a) committed by a registered manufacturer or distributor of opioids that relates to the reporting of suspicious orders for opioids, failing to maintain effective controls against diversion of opioids, or failing to review the most recent information made available by the Attorney General in accordance with section 827(f) of this title, the criminal fine under title 18 shall not exceed $500,000.

(3)

Except under the conditions specified in paragraph (2) of this subsection, a violation of this section does not constitute a crime, and a judgment for the United States and imposition of a civil penalty pursuant to paragraph (1) shall not give rise to any disability or legal disadvantage based on conviction for a criminal offense.

(4)
(A)

If a regulated seller, or a distributor required to submit reports under section 830(b)(3) of this title, violates paragraph (12) of subsection (a) of this section, or if a regulated seller violates paragraph (13) of such subsection, the Attorney General may by order prohibit such seller or distributor (as the case may be) from selling any scheduled listed chemical product. Any sale of such a product in violation of such an order is subject to the same penalties as apply under paragraph (2).

(B)

An order under subparagraph (A) may be imposed only through the same procedures as apply under section 824(c) of this title for an order to show cause.

Footnotes

  1. 1 So in original. Probably should be “section 830(a)(3) of this title;”.
  2. 2 See References in Text note below.

Legislative history

Reconstructed from this section’s Code source credit and amendment notes, resolved against the local Statutes at Large. Editorial notes are evidence, not the law that made the change.

  1. Controlled Substances Act

    Pub. L. 91–513 title II § 402 · 84 Stat. 1236

    Enacted · 21 U.S.C. § 842

    Pub. L. 91–513, title II, § 402, Oct. 27, 1970, 84 Stat. 1262

    Source evidence

    Code source credit
    Pub. L. 91–513, title II, § 402, Oct. 27, 1970, 84 Stat. 1262

    Enacted provision · exact public law section
    Sec. 402. prohibited acts—penalties (a) It shall be unlawful for any person— (1) who is subject to the requirements of part C to distribute or dispense a controlled substance in violation of section 309; (2) who is a registrant to distribute or dispense a controlled substance not authorized by his registration to another registrant, or other authorized person or to manufacture a controlled substance not authorized by his registration; (3) who is a registrant to distribute a controlled substance in violation of section 305 of this title; (4) to remove, alter, or obliterate a symbol or label required by section 305 of this title: (5) to refuse or fail to make, keep, or furnish any record, report, notification, declaration, order or order form, statement, Post, p. 1285 invoice, or information required under this title or title III; (6) to refuse any entry into any premises or inspection authorized by this title or title III; (7) to remove, break, injure, or deface a seal placed upon controlled Ante, p. 1256 Post, p. 1276 substances pursuant to section 304(f) or 511 or to remove or dispose of substances so placed under seal; or (8) to use, to his own advantage, or to reveal, other than to duly authorized officers or employees of the United States, or to the courts when relevant in any judicial proceeding under this title or title III, any information acquired in the course of an inspection authorized by this title concerning any method or process which as a trade secret is entitled to protection. (b) It shall be unlawful for any person who is a registrant to manufacture a controlled substance in schedule I or II which is— (1) not expressly authorized by his registration and by a quota assigned to him pursuant to section 306; or (2) in excess of a quota assigned to him pursuant to section 306. (c) (1) Except as provided in paragraph (2), any person who violates this section shall, with respect to any such violation, be subject Jurisdiction. to a civil penalty of not more than $25,000. The district courts of the United States (or, where there is no such court in the ease of any territory or possession of the United States, then the court in such territory or possession having the jurisdiction of a district court of the United States in cases arising under the Constitution and laws of the United States) shall have jurisdiction in accordance with section 1355 62 Stat. 934. of title 28 of the United States Code to enforce this paragraph. (2) (A) If a violation of this section is prosecuted by an information or indictment which alleges that the violation was committed knowingly and the trier of fact specifically finds that the violation was so committed, such person shall, except as otherwise provided in subparagraph (B) of this paragraph, be sentenced to imprisonment of Penalty. not more than one year or a fine of not more than $25,000, or both. (B) If a violation referred to in subparagraph (A) was committed after one or more prior convictions of the offender for an offense punishable under this paragraph (2), or for a crime under any other provision of this title or title III or other law of the United States Post, p. 1285. relating to narcotic drugs, marihuana, or depressant or stimulant substances, have become final, such person shall be sentenced to a term Penalty. of imprisonment of not more than 2 years, a fine of $50,000, or both. (3) Except under the conditions specified in paragraph (2) of Exception. this subsection, a violation of this section does not constitute a crime, and a judgment for the United States and imposition of a civil penalty Pursuant to paragraph (1) shall not give rise to any disability or legal disadvantage based on conviction for a criminal offense.

  2. Psychotropic Substances Act of 1978

    Pub. L. 95–633 § 202(b)(1) · 92 Stat. 3768

    Added · 21 U.S.C. § 842(a)(9)

    Pub. L. 95–633, § 202(b)(1), added par. (9)

    Source evidence

    Code amendment note
    Subsec. (a)(9). Pub. L. 95–633, § 202(b)(1), added par. (9).

    Enacted provision · exact public law section
    (1) Section 402 (a) of such Act (21 U.S.C. 842(a)) is amended— (A) by striking out “or” at the end of paragraph (7); (B) by striking out the period at the end of paragraph (8) and inserting in lieu thereof “; or”; and (C) by adding after paragraph (8) the following new paragraph: “(9) to distribute or sell piperidine in violation of regulations Ante, p. 3775. established under section 310(a)(2), respecting presentation of identification.”.

  3. Psychotropic Substances Act of 1978

    Pub. L. 95–633 § 202(b)(2) · 92 Stat. 3768

    Added · 21 U.S.C. § 842(c)(2)(C)

    Pub. L. 95–633, § 202(b)(2), added subpar. (C)

    Source evidence

    Code amendment note
    Subsec. (c)(2)(C). Pub. L. 95–633, § 202(b)(2), added subpar. (C).

    Enacted provision · exact public law section
    (2) Section 402(c)(2) of such Act (21 U.S.C. 842(c)(2)) is amended by adding after subparagraph (B) the following new subparagraph: “(C) Subparagraphs (A) and (B) shall not apply to a violation of subsection (a)(5) with respect to a refusal or failure to make a report required under section 310(a) (relating to piperidine reporting)”.

  4. Chemical Diversion and Trafficking Act of 1988

    Pub. L. 100–690 § 6056(a) · 102 Stat. 4181

    Inserted · 21 U.S.C. § 842(a)(8)

    Pub. L. 100–690, § 6056(a), inserted “, or to use to his own advantage or reveal (other than as authorized by section 830 of this title) any information that is confidential under such section” after “protection”

    Source evidence

    Code amendment note
    Subsec. (a)(8). Pub. L. 100–690, § 6056(a), inserted “, or to use to his own advantage or reveal (other than as authorized by section 830 of this title) any information that is confidential under such section” after “protection”.

    Enacted provision · exact public law section
    (a) Confidential Information Amendment.— Section 402(a)(8) of the Controlled Substances Act (21 U.S.C. 842(a)(8)) is amended by inserting after “protection” the following: “, or to use to his own advantage or reveal (other than as authorized by section 310) any information that is confidential under such section”.

  5. Chemical Diversion and Trafficking Act of 1988

    Pub. L. 100–690 § 6056(b) · 102 Stat. 4181

    Amended · 21 U.S.C. § 842(a)(9)

    Pub. L. 100–690, § 6056(b), amended par. (9) generally. Prior to amendment, par. (9) read as follows: “to distribute or sell piperidine in violation of regulations established under section 830(a)(2) of this title, respecting presentation of identification.”

    Source evidence

    Code amendment note
    Subsec. (a)(9). Pub. L. 100–690, § 6056(b), amended par. (9) generally. Prior to amendment, par. (9) read as follows: “to distribute or sell piperidine in violation of regulations established under section 830(a)(2) of this title, respecting presentation of identification.”

    Enacted provision · exact public law section
    (b) Identification Amendment.— Section 402(a)(9) of the Controlled Substances Act (21 U.S.C. 842(a)(9)) is amended to read as follows: “(9) who is a regulated person to engage in a regulated transaction without obtaining the identification required by 310(a)(3).”.

  6. Chemical Diversion and Trafficking Act of 1988

    Pub. L. 100–690 § 6056(d) · 102 Stat. 4181

    Added · 21 U.S.C. § 842(a)(10)

    Pub. L. 100–690, § 6056(d), added par. (10)

    Source evidence

    Code amendment note
    Subsec. (a)(10). Pub. L. 100–690, § 6056(d), added par. (10).

    Enacted provision · exact public law section
    (d) Records Violations.— Section 402(a) of the Controlled Substances Act (21 U.S.C. 842(a)) is amended— (1) in paragraph (8), as amended by subsection (a) of this section, by striking out “or” at the end of the paragraph; (2) in paragraph (9), as amended by subsection (b) of this section, by striking out the period at the end of the paragraph and inserting in lieu thereof “; or”; and (3) by adding at the end the following new paragraph: “(10) to fail to keep a record or make a report under section 310.”.

  7. Chemical Diversion and Trafficking Act of 1988

    Pub. L. 100–690 § 6056(c) · 102 Stat. 4181

    Struck · 21 U.S.C. § 842(c)(2)(C)

    Pub. L. 100–690, § 6056(c), struck out subpar. (C) which read as follows: “Subparagraphs (A) and (B) shall not apply to a violation of subsection (a)(5) of this section with respect to a refusal or failure to make a report required under section 830(a) of this title (relating to piperidine reporting).”

    Source evidence

    Code amendment note
    Subsec. (c)(2)(C). Pub. L. 100–690, § 6056(c), struck out subpar. (C) which read as follows: “Subparagraphs (A) and (B) shall not apply to a violation of subsection (a)(5) of this section with respect to a refusal or failure to make a report required under section 830(a) of this title (relating to piperidine reporting).”

    Enacted provision · exact public law section
    (c) Technical Amendment.— Section 402(c)(2) of the Controlled Substances Act (21 U.S.C. 842(c)(2)) is amended by striking out subparagraph (C).

  8. Comprehensive Methamphetamine Control Act of 1996

    Pub. L. 104–237 § 205(a) · 110 Stat. 3099

    Added · 21 U.S.C. § 842(a)

    Pub. L. 104–237, § 205(a), added par. (11) and closing provisions

    Source evidence

    Code amendment note
    Subsec. (a). Pub. L. 104–237, § 205(a), added par. (11) and closing provisions.

    Enacted provision · exact public law section
    (a) Offenses.— Section 402(a) of the Controlled Substances Act (21 U.S.C. 842(a)) is amended— (1) in paragraph (9), by striking “or” after the semicolon; (2) in paragraph (10), by striking the period and inserting “; or”; and (3) by adding at the end the following: “(11) to distribute a laboratory supply to a person who uses, or attempts to use, that laboratory supply to manufacture a controlled substance or a listed chemical, in violation of this title or title III, with reckless disregard for the illegal uses to which such a laboratory supply will be put. As used in paragraph (11), the term ‘laboratory supply’ means a listed chemical or any chemical, substance, or item on a special surveillance list published by the Attorney General, which contains chemicals, products, materials, or equipment used in the manufacture of controlled substances and listed chemicals. For purposes of paragraph (11), there is a rebuttable presumption of reckless disregard at trial if the Attorney General notifies a firm in writing that a laboratory supply sold by the firm, or any other person or firm, has been used by a customer of the notified firm, or distributed further by that customer, for the unlawful production of controlled substances or listed chemicals a firm distributes and 2 weeks or more after the notification the notified firm distributes a laboratory supply to the customer.”.

  9. Comprehensive Methamphetamine Control Act of 1996

    Pub. L. 104–237 § 205(b) · 110 Stat. 3099

    Added · 21 U.S.C. § 842(c)(2)(C)

    Pub. L. 104–237, § 205(b), added subpar. (C)

    Source evidence

    Code amendment note
    Subsec. (c)(2)(C). Pub. L. 104–237, § 205(b), added subpar. (C).

    Enacted provision · exact public law section
    (b) Civil Penalty.— Section 402(c)(2) of the Controlled Substances Act (21 U.S.C. 842(c)(2)) is amended by adding at the end the following: “(C) In addition to the penalties set forth elsewhere in this title or title III, any business that violates paragraph (11) of subsection (a) shall, with respect to the first such violation, be subject to a civil penalty of not more than $250,000, but shall not be subject to criminal penalties under this section, and shall, for any succeeding violation, be subject to a civil fine of not more than $250,000 or double the last previously imposed penalty, whichever is greater.”.

  10. Pub. L. 105–277 § 101(b)(tI)(s117)(1) · 112 Stat. 2681

    Inserted · 21 U.S.C. § 842(a)(5)

    Pub. L. 105–277, § 101(b) [title I, § 117(1)], inserted “negligently” before “fail”

    Source evidence

    Code amendment note
    Subsec. (a)(5). Pub. L. 105–277, § 101(b) [title I, § 117(1)], inserted “negligently” before “fail”.

    Enacted provision · exact public law section
    Sec. 101. For programs, projects or activities in the Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 1999, provided as follows, to be effective as if it had been enacted into law as the regular appropriations Act: AN ACT Making appropriations for Agriculture, Rural Development, Food and Drug Administration, and Related Agencies programs for the fiscal year ending September 30, 1999, and for other purposes. Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 1999.

  11. Pub. L. 105–277 § 101(b)(tI)(s117)(2) · 112 Stat. 2681

    Inserted · 21 U.S.C. § 842(a)(10)

    Pub. L. 105–277, § 101(b) [title I, § 117(2)], inserted “negligently” before “to fail”

    Source evidence

    Code amendment note
    Subsec. (a)(10). Pub. L. 105–277, § 101(b) [title I, § 117(2)], inserted “negligently” before “to fail”.

    Enacted provision · exact public law section
    Sec. 101. For programs, projects or activities in the Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 1999, provided as follows, to be effective as if it had been enacted into law as the regular appropriations Act: AN ACT Making appropriations for Agriculture, Rural Development, Food and Drug Administration, and Related Agencies programs for the fiscal year ending September 30, 1999, and for other purposes. Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 1999.

  12. Pub. L. 105–277 § 101(b)(tI)(s117)(3) · 112 Stat. 2681

    1. Amended · 21 U.S.C. § 842(c)(1)

      Pub. L. 105–277, § 101(b) [title I, § 117(3)], designated existing provisions as subpar. (A)

    2. Inserted · 21 U.S.C. § 842(c)(1)

      Pub. L. 105–277, § 101(b) [title I, § 117(3)], inserted “subparagraph (B) of this paragraph and” before “paragraph (2)”

    3. Added · 21 U.S.C. § 842(c)(1)

      Pub. L. 105–277, § 101(b) [title I, § 117(3)], added subpar. (B)

    Source evidence

    Code amendment note
    Subsec. (c)(1). Pub. L. 105–277, § 101(b) [title I, § 117(3)], designated existing provisions as subpar. (A), inserted “subparagraph (B) of this paragraph and” before “paragraph (2)”, and added subpar. (B).

    Enacted provision · exact public law section
    Sec. 101. For programs, projects or activities in the Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 1999, provided as follows, to be effective as if it had been enacted into law as the regular appropriations Act: AN ACT Making appropriations for Agriculture, Rural Development, Food and Drug Administration, and Related Agencies programs for the fiscal year ending September 30, 1999, and for other purposes. Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 1999.

  13. Criminal Law Technical Amendments Act of 2002

    Pub. L. 107–273 § 4002(d)(2)(B)(i) · 116 Stat. 1758

    Substituted · 21 U.S.C. § 842(c)(2)(A)

    Pub. L. 107–273, § 4002(d)(2)(B)(i), substituted “under title 18” for “of not more than $25,000”

    Source evidence

    Code amendment note
    Subsec. (c)(2)(A). Pub. L. 107–273, § 4002(d)(2)(B)(i), substituted “under title 18” for “of not more than $25,000”.

    Enacted provision · exact public law section
    (i) in subparagraph (A), by striking “of not more than $25,000” and inserting “under title 18, United States Code”; and

  14. Criminal Law Technical Amendments Act of 2002

    Pub. L. 107–273 § 4002(d)(2)(B)(ii) · 116 Stat. 1758

    Substituted · 21 U.S.C. § 842(c)(2)(B)

    Pub. L. 107–273, § 4002(d)(2)(B)(ii), substituted “under title 18” for “of $50,000”

    Source evidence

    Code amendment note
    Subsec. (c)(2)(B). Pub. L. 107–273, § 4002(d)(2)(B)(ii), substituted “under title 18” for “of $50,000”.

    Enacted provision · exact public law section
    (ii) in subparagraph (B), by striking “of $50,000” and inserting “under title 18, United States Code”.

  15. Criminal Law Technical Amendments Act of 2002

    Pub. L. 107–273 § 4002(b)(16) · 116 Stat. 1758

    Changed · 21 U.S.C. § 842(c)(2)(C)

    Pub. L. 107–273, § 4002(b)(16), realigned margins

    Source evidence

    Code amendment note
    Subsec. (c)(2)(C). Pub. L. 107–273, § 4002(b)(16), realigned margins.

    Enacted provision · exact public law section
    (16) Correction of indentation in controlled substances act.— Section 402(c)(2) of the Controlled Substances Act (21 U.S.C. 842(c)(2)) is amended by moving the margin of subparagraph (C) 2 ems to the left.

  16. Combat Methamphetamine Epidemic Act of 2005

    Pub. L. 109–177 § 711(f)(1)(A) · 120 Stat. 192

    Added · 21 U.S.C. § 842(a)(12)(14)

    Pub. L. 109–177, § 711(f)(1)(A), added pars. (12) to (14)

    Source evidence

    Code amendment note
    Subsec. (a)(12) to (14). Pub. L. 109–177, § 711(f)(1)(A), added pars. (12) to (14).

    Enacted provision · exact public law section
    (A) In general.— Section 402(a) of the Controlled Substances Act (21 U.S.C. 842(a)) is amended— (i) in paragraph (10), by striking “or” after the semicolon; (ii) in paragraph (11), by striking the period at the end and inserting a semicolon; and (iii) by inserting after paragraph (11) the following paragraphs: “(12) who is a regulated seller, or a distributor required to submit reports under subsection (b)(3) of section 310— “(A) to sell at retail a scheduled listed chemical product in violation of paragraph (1) of subsection (d) of such section, knowing at the time of the transaction involved (independent of consulting the logbook under subsection (e)(1)(A)(iii) of such section) that the transaction is a violation; or “(B) to knowingly or recklessly sell at retail such a product in violation of paragraph (2) of such subsection (d); “(13) who is a regulated seller to knowingly or recklessly sell at retail a scheduled listed chemical product in violation of subsection (e) of such section; or “(14) who is a regulated seller or an employee or agent of such seller to disclose, in violation of regulations under subparagraph (C) of section 310(e)(1), information in logbooks under subparagraph (A)(iii) of such section, or to refuse to provide such a logbook to Federal, State, or local law enforcement authorities.” .

  17. Combat Methamphetamine Epidemic Act of 2005

    Pub. L. 109–177 § 714 · 120 Stat. 192

    Inserted · 21 U.S.C. § 842(b)

    Pub. L. 109–177, § 714, inserted “, or ephedrine, pseudoephedrine, or phenylpropanolamine or any of the salts, optical isomers, or salts of optical isomers of such chemical,” after “manufacture a controlled substance in schedule I or II” in introductory provisions

    Source evidence

    Code amendment note
    Subsec. (b). Pub. L. 109–177, § 714, inserted “, or ephedrine, pseudoephedrine, or phenylpropanolamine or any of the salts, optical isomers, or salts of optical isomers of such chemical,” after “manufacture a controlled substance in schedule I or II” in introductory provisions.

    Enacted provision · exact public law section
    SEC. 714. PENALTIES; AUTHORITY FOR MANUFACTURING; QUOTA.   Section 402(b) of the Controlled Substances Act (21 U.S.C. 842(b)) is amended by inserting after “manufacture a controlled substance in schedule I or II” the following: “, or ephedrine, pseudoephedrine, or phenylpropanolamine or any of the salts, optical isomers, or salts of optical isomers of such chemical,”.

  18. Combat Methamphetamine Epidemic Act of 2005

    Pub. L. 109–177 § 711(f)(2) · 120 Stat. 192

    Added · 21 U.S.C. § 842(c)(4)

    Pub. L. 109–177, § 711(f)(2), added par. (4)

    Source evidence

    Code amendment note
    Subsec. (c)(4). Pub. L. 109–177, § 711(f)(2), added par. (4).

    Enacted provision · exact public law section
    (2) Authority to prohibit sales by violators.— Section 402(c) of the Controlled Substances Act (21 U.S.C. 842(c)) is amended by adding at the end the following paragraph: “(4) (A) If a regulated seller, or a distributor required to submit reports under section 310(b)(3), violates paragraph (12) of subsection (a) of this section, or if a regulated seller violates paragraph (13) of such subsection, the Attorney General may by order prohibit such seller or distributor (as the case may be) from selling any scheduled listed chemical product. Any sale of such a product in violation of such an order is subject to the same penalties as apply under paragraph (2). “(B) An order under subparagraph (A) may be imposed only through the same procedures as apply under section 304(c) for an order to show cause.” .

  19. Combat Methamphetamine Enhancement Act of 2010

    Pub. L. 111–268 § 4(4) · 124 Stat. 2847

    Inserted · 21 U.S.C. § 842(a)

    Pub. L. 111–268, § 4(4), inserted “For purposes of paragraph (15), if the distributor is temporarily unable to access the list of persons referred to under section 830(e)(1)(B)(v) of this title, the distributor may rely on a written, faxed, or electronic copy of a certificate of self-certification submitted by the regulated seller or regulated person, provided the distributor confirms within 7 business days of the distribution that such regulated seller or regulated person is on the list referred to under section 830(e)(1)(B)(v) of this title.” at end of concluding provisions

    Source evidence

    Code amendment note
    Subsec. (a). Pub. L. 111–268, § 4(4), inserted “For purposes of paragraph (15), if the distributor is temporarily unable to access the list of persons referred to under section 830(e)(1)(B)(v) of this title, the distributor may rely on a written, faxed, or electronic copy of a certificate of self-certification submitted by the regulated seller or regulated person, provided the distributor confirms within 7 business days of the distribution that such regulated seller or regulated person is on the list referred to under section 830(e)(1)(B)(v) of this title.” at end of concluding provisions.

    Enacted provision · exact public law section
    (4) Deadline. by inserting at the end the following: “For purposes of paragraph (15), if the distributor is temporarily unable to access the list of persons referred to under section 310(e)(1)(B)(v), the distributor may rely on a written, faxed, or electronic copy of a certificate of self-certification submitted by the regulated seller or regulated person, provided the distributor confirms within 7 business days of the distribution that such regulated seller or regulated person is on the list referred to under section 310(e)(1)(B)(v).”.

    Effective date note
    Amendment by Pub. L. 111–268 effective 180 days after Oct. 12, 2010, see section 6(a) of Pub. L. 111–268, set out as a note under section 830 of this title.

  20. Combat Methamphetamine Enhancement Act of 2010

    Pub. L. 111–268 § 5 · 124 Stat. 2847

    Inserted · 21 U.S.C. § 842(a)(10)

    Pub. L. 111–268, § 5, inserted “or negligently to fail to self-certify as required under section 830 of this title” before semicolon

    Source evidence

    Code amendment note
    Subsec. (a)(10). Pub. L. 111–268, § 5, inserted “or negligently to fail to self-certify as required under section 830 of this title” before semicolon.

    Enacted provision · exact public law section
    SEC. 5. NEGLIGENT FAILURE TO SELF-CERTIFY AS REQUIRED.   Section 402(a)(10) of the Controlled Substances Act (21 U.S.C. 842(a)(10)) is amended by inserting before the semicolon the following: “or negligently to fail to self-certify as required under section 310”.

    Effective date note
    Amendment by Pub. L. 111–268 effective 180 days after Oct. 12, 2010, see section 6(a) of Pub. L. 111–268, set out as a note under section 830 of this title.

  21. Combat Methamphetamine Enhancement Act of 2010

    Pub. L. 111–268 § 4(1) · 124 Stat. 2847

    Added · 21 U.S.C. § 842(a)(15)

    Pub. L. 111–268, § 4(1)–(3), added par. (15)

    Source evidence

    Code amendment note
    Subsec. (a)(15). Pub. L. 111–268, § 4(1)–(3), added par. (15).

    Enacted provision · exact public law section
    (1) in paragraph (13), by striking “or” after the semicolon;

    Effective date note
    Amendment by Pub. L. 111–268 effective 180 days after Oct. 12, 2010, see section 6(a) of Pub. L. 111–268, set out as a note under section 830 of this title.

  22. Designer Anabolic Steroid Control Act of 2014

    Pub. L. 113–260 § 3(c)(1) · 128 Stat. 2929

    Added · 21 U.S.C. § 842(a)(16)

    Pub. L. 113–260, § 3(c)(1), added par. (16)

    Source evidence

    Code amendment note
    Subsec. (a)(16). Pub. L. 113–260, § 3(c)(1), added par. (16).

    Enacted provision · exact public law section
    (1) in subsection (a)— (A) in paragraph (14), by striking “or” at the end; (B) in paragraph (15), by striking the period at the end and inserting “; or”; and (C) by inserting, after paragraph (15), the following: “(16) to violate subsection (e) of section 825 of this title.” ; and

  23. Designer Anabolic Steroid Control Act of 2014

    Pub. L. 113–260 § 3(c)(2)(A) · 128 Stat. 2929

    Inserted · 21 U.S.C. § 842(c)(1)(A)

    Pub. L. 113–260, § 3(c)(2)(A), inserted “, (C), or (D)” after “subparagraph (B)”

    Source evidence

    Code amendment note
    Subsec. (c)(1)(A). Pub. L. 113–260, § 3(c)(2)(A), inserted “, (C), or (D)” after “subparagraph (B)”.

    Enacted provision · exact public law section
    (A) by inserting, in subparagraph (A), after “subparagraph (B)” the following: “, (C), or (D)”; and

  24. Designer Anabolic Steroid Control Act of 2014

    Pub. L. 113–260 § 3(c)(2)(B) · 128 Stat. 2929

    Added · 21 U.S.C. § 842(c)(1)(C); 21 U.S.C. § 842(c)(1)(D)

    Pub. L. 113–260, § 3(c)(2)(B), added subpars. (C) and (D)

    Source evidence

    Code amendment note
    Subsec. (c)(1)(C), (D). Pub. L. 113–260, § 3(c)(2)(B), added subpars. (C) and (D).

    Enacted provision · exact public law section
    (B) Definitions. by inserting after subparagraph (B) the following: “(C) In the case of a violation of paragraph (16) of subsection (a) of this section by an importer, exporter, manufacturer, or distributor (other than as provided in subparagraph (D)), up to $500,000 per violation. For purposes of this subparagraph, a violation is defined as each instance of importation, exportation, manufacturing, distribution, or possession with intent to manufacture or distribute, in violation of paragraph (16) of subsection (a). “(D) In the case of a distribution, dispensing, or possession with intent to distribute or dispense in violation of paragraph (16) of subsection (a) of this section at the retail level, up to $1000 per violation. For purposes of this paragraph, the term ‘at the retail level’ refers to products sold, or held for sale, directly to the consumer for personal use. Each package, container or other separate unit containing an anabolic steroid that is distributed, dispensed, or possessed with intent to distribute or dispense at the retail level in violation of such paragraph (16) of subsection (a) shall be considered a separate violation.” .

  25. Using Data To Prevent Opioid Diversion Act of 2018

    Pub. L. 115–271 § 3273(c)(1) · 132 Stat. 3894

    Added · 21 U.S.C. § 842(a)(17)

    Pub. L. 115–271, § 3273(c)(1), added par. (17)

    Source evidence

    Code amendment note
    Subsec. (a)(17). Pub. L. 115–271, § 3273(c)(1), added par. (17).

    Enacted provision · exact public law section
    (1) in subsection (a)— (A) in paragraph (15), by striking “or” at the end; (B) in paragraph (16), by striking the period at the end and inserting “; or”; and (C) by inserting after paragraph (16) the following: “(17) in the case of a registered manufacturer or distributor of opioids, to fail to review the most recent information, directly related to the customers of the manufacturer or distributor, made available by the Attorney General in accordance with section 307(f).” ; and

  26. Using Data To Prevent Opioid Diversion Act of 2018

    Pub. L. 115–271 § 3273(c)(2)(A) · 132 Stat. 3894

    1. Added · 21 U.S.C. § 842(c)(1)(B)

      Pub. L. 115–271, § 3273(c)(2)(A), added subpar. (B)

    2. Struck · 21 U.S.C. § 842(c)(1)(B)

      Pub. L. 115–271, § 3273(c)(2)(A), struck out former subpar. (B) which read as follows: “In the case of a violation of paragraph (5) or (10) of subsection (a), the civil penalty shall not exceed $10,000.”

    Source evidence

    Code amendment note
    Subsec. (c)(1)(B). Pub. L. 115–271, § 3273(c)(2)(A), added subpar. (B) and struck out former subpar. (B) which read as follows: “In the case of a violation of paragraph (5) or (10) of subsection (a), the civil penalty shall not exceed $10,000.”

    Enacted provision · exact public law section
    (A) in paragraph (1), by striking subparagraph (B) and inserting the following: “(B) (i) Except as provided in clause (ii), in the case of a violation of paragraph (5), (10), or (17) of subsection (a), the civil penalty shall not exceed $10,000. “(ii) In the case of a violation described in clause (i) committed by a registered manufacturer or distributor of opioids and related to the reporting of suspicious orders for opioids, failing to maintain effective controls against diversion of opioids, or failing to review the most recent information made available by the Attorney General in accordance with section 307(f), the penalty shall not exceed $100,000.” ; and

  27. Using Data To Prevent Opioid Diversion Act of 2018

    Pub. L. 115–271 § 3273(c)(2)(B)(i) · 132 Stat. 3894

    Inserted · 21 U.S.C. § 842(c)(2)(A)

    Pub. L. 115–271, § 3273(c)(2)(B)(i), inserted “or (D)” after “subparagraph (B)”

    Source evidence

    Code amendment note
    Subsec. (c)(2)(A). Pub. L. 115–271, § 3273(c)(2)(B)(i), inserted “or (D)” after “subparagraph (B)”.

    Enacted provision · exact public law section
    (i) in subparagraph (A), by inserting “or (D)” after “subparagraph (B)”; and

  28. Using Data To Prevent Opioid Diversion Act of 2018

    Pub. L. 115–271 § 3273(c)(2)(B)(ii) · 132 Stat. 3894

    Added · 21 U.S.C. § 842(c)(2)(D)

    Pub. L. 115–271, § 3273(c)(2)(B)(ii), added subpar. (D)

    Source evidence

    Code amendment note
    Subsec. (c)(2)(D). Pub. L. 115–271, § 3273(c)(2)(B)(ii), added subpar. (D).

    Enacted provision · exact public law section
    (ii) by adding at the end the following: “(D) In the case of a violation described in subparagraph (A) that was a violation of paragraph (5), (10), or (17) of subsection (a) committed by a registered manufacturer or distributor of opioids that relates to the reporting of suspicious orders for opioids, failing to maintain effective controls against diversion of opioids, or failing to review the most recent information made available by the Attorney General in accordance with section 307(f), the criminal fine under title 18, United States Code, shall not exceed $500,000.” .

31 of 31 references resolved to an enrolled provision

Editorial Notes

References in Text

Section 825 of this title, referred to in subsec. (a)(16), was so in the original, but probably should have been a reference to section 305 of Pub. L. 91–513, which is classified to section 825 of this title.

Schedules I and II, referred to in subsec. (b), are set out in section 812(c) of this title.

Amendments1978–2018 · 9 rounds

2018

Subsec. (a)(17). Pub. L. 115–271, § 3273(c)(1), added par. (17).

Subsec. (c)(1)(B). Pub. L. 115–271, § 3273(c)(2)(A), added subpar. (B) and struck out former subpar. (B) which read as follows: “In the case of a violation of paragraph (5) or (10) of subsection (a), the civil penalty shall not exceed $10,000.”

Subsec. (c)(2)(A). Pub. L. 115–271, § 3273(c)(2)(B)(i), inserted “or (D)” after “subparagraph (B)”.

Subsec. (c)(2)(D). Pub. L. 115–271, § 3273(c)(2)(B)(ii), added subpar. (D).

2014

Subsec. (a)(16). Pub. L. 113–260, § 3(c)(1), added par. (16).

Subsec. (c)(1)(A). Pub. L. 113–260, § 3(c)(2)(A), inserted “, (C), or (D)” after “subparagraph (B)”.

Subsec. (c)(1)(C), (D). Pub. L. 113–260, § 3(c)(2)(B), added subpars. (C) and (D).

2010

Subsec. (a). Pub. L. 111–268, § 4(4), inserted “For purposes of paragraph (15), if the distributor is temporarily unable to access the list of persons referred to under section 830(e)(1)(B)(v) of this title, the distributor may rely on a written, faxed, or electronic copy of a certificate of self-certification submitted by the regulated seller or regulated person, provided the distributor confirms within 7 business days of the distribution that such regulated seller or regulated person is on the list referred to under section 830(e)(1)(B)(v) of this title.” at end of concluding provisions.

Subsec. (a)(10). Pub. L. 111–268, § 5, inserted “or negligently to fail to self-certify as required under section 830 of this title” before semicolon.

Subsec. (a)(15). Pub. L. 111–268, § 4(1)–(3), added par. (15).

2006

Subsec. (a)(12) to (14). Pub. L. 109–177, § 711(f)(1)(A), added pars. (12) to (14).

Subsec. (b). Pub. L. 109–177, § 714, inserted “, or ephedrine, pseudoephedrine, or phenylpropanolamine or any of the salts, optical isomers, or salts of optical isomers of such chemical,” after “manufacture a controlled substance in schedule I or II” in introductory provisions.

Subsec. (c)(4). Pub. L. 109–177, § 711(f)(2), added par. (4).

2002

Subsec. (c)(2)(A). Pub. L. 107–273, § 4002(d)(2)(B)(i), substituted “under title 18” for “of not more than $25,000”.

Subsec. (c)(2)(B). Pub. L. 107–273, § 4002(d)(2)(B)(ii), substituted “under title 18” for “of $50,000”.

Subsec. (c)(2)(C). Pub. L. 107–273, § 4002(b)(16), realigned margins.

1998

Subsec. (a)(5). Pub. L. 105–277, § 101(b) [title I, § 117(1)], inserted “negligently” before “fail”.

Subsec. (a)(10). Pub. L. 105–277, § 101(b) [title I, § 117(2)], inserted “negligently” before “to fail”.

Subsec. (c)(1). Pub. L. 105–277, § 101(b) [title I, § 117(3)], designated existing provisions as subpar. (A), inserted “subparagraph (B) of this paragraph and” before “paragraph (2)”, and added subpar. (B).

1996

Subsec. (a). Pub. L. 104–237, § 205(a), added par. (11) and closing provisions.

Subsec. (c)(2)(C). Pub. L. 104–237, § 205(b), added subpar. (C).

1988

Subsec. (a)(8). Pub. L. 100–690, § 6056(a), inserted “, or to use to his own advantage or reveal (other than as authorized by section 830 of this title) any information that is confidential under such section” after “protection”.

Subsec. (a)(9). Pub. L. 100–690, § 6056(b), amended par. (9) generally. Prior to amendment, par. (9) read as follows: “to distribute or sell piperidine in violation of regulations established under section 830(a)(2) of this title, respecting presentation of identification.”

Subsec. (a)(10). Pub. L. 100–690, § 6056(d), added par. (10).

Subsec. (c)(2)(C). Pub. L. 100–690, § 6056(c), struck out subpar. (C) which read as follows: “Subparagraphs (A) and (B) shall not apply to a violation of subsection (a)(5) of this section with respect to a refusal or failure to make a report required under section 830(a) of this title (relating to piperidine reporting).”

1978

Subsec. (a)(9). Pub. L. 95–633, § 202(b)(1), added par. (9).

Subsec. (c)(2)(C). Pub. L. 95–633, § 202(b)(2), added subpar. (C).

Statutory Notes and Related Subsidiaries

Effective Date of 2010 Amendment

Amendment by Pub. L. 111–268 effective 180 days after , see section 6(a) of Pub. L. 111–268, set out as a note under section 830 of this title.

Effective Date of 1988 Amendment

Amendment by Pub. L. 100–690 effective 120 days after , see section 6061 of Pub. L. 100–690, set out as a note under section 802 of this title.

Effective Date of 1978 Amendment

Amendment by Pub. L. 95–633 effective , see section 203(a) of Pub. L. 95–633 set out as an Effective Date note under section 830 of this title.

Effective Date

Section effective on first day of seventh calendar month that begins after , see section 704 of Pub. L. 91–513, set out as a note under section 801 of this title.

Repeals

Pub. L. 96–359, § 8(b), , 94 Stat. 1194, repealed section 203(d) of Pub. L. 95–633, which had provided for the repeal of subsecs. (a)(9) and (c)(2)(C) of this section effective .

Credits

1970–2018 · 10 acts
  1. 1970Pub. L. 91–513, title II, § 402, , 84 Stat. 1262
  2. 1978Pub. L. 95–633, title II, § 202(b)(1), (2), , 92 Stat. 3776
  3. 1988Pub. L. 100–690, title VI, § 6056, , 102 Stat. 4318
  4. 1996Pub. L. 104–237, title II, § 205, , 110 Stat. 3103
  5. 1998Pub. L. 105–277, div. A, § 101(b) [title I, § 117], , 112 Stat. 2681–50, 2681–68
  6. 2002Pub. L. 107–273, div. B, title IV, § 4002(b)(16), (d)(2)(B), , 116 Stat. 1808, 1809
  7. 2006Pub. L. 109–177, title VII, §§ 711(f)(1)(A), (2), 714, , 120 Stat. 262–264
  8. 2010Pub. L. 111–268, §§ 4, 5, , 124 Stat. 2847, 2848
  9. 2014Pub. L. 113–260, § 3(c), , 128 Stat. 2931
  10. 2018Pub. L. 115–271, title III, § 3273(c), , 132 Stat. 3953.
Show as published

(Pub. L. 91–513, title II, § 402, , 84 Stat. 1262; Pub. L. 95–633, title II, § 202(b)(1), (2), , 92 Stat. 3776; Pub. L. 100–690, title VI, § 6056, , 102 Stat. 4318; Pub. L. 104–237, title II, § 205, , 110 Stat. 3103; Pub. L. 105–277, div. A, § 101(b) [title I, § 117], , 112 Stat. 2681–50, 2681–68; Pub. L. 107–273, div. B, title IV, § 4002(b)(16), (d)(2)(B), , 116 Stat. 1808, 1809; Pub. L. 109–177, title VII, §§ 711(f)(1)(A), (2), 714, , 120 Stat. 262–264; Pub. L. 111–268, §§ 4, 5, , 124 Stat. 2847, 2848; Pub. L. 113–260, § 3(c), , 128 Stat. 2931; Pub. L. 115–271, title III, § 3273(c), , 132 Stat. 3953.)

Parsed from the official OLRC USLM XML in data/usc_all/usc21.xml · release point 119-108 · OLRC build 2026-04-17

USLM identifier /us/usc/t21/s842